Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.

ABSTRACT:

Aims

This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).

Methods

This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82). Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.

Results

All three agents led to significant weight loss. Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001). Dose-dependent reductions were observ

SUBMITTER: Al Ozairi E 

PROVIDER: S-EPMC12673458 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature